Where are we
Training at VHIR
VHIR in the media
The European Medicines Agency grants the "orphan drug" designation to a viral vector tested in VHIR
The European Medicines Agency (EMA) approves the first viral vector for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare and lethal autosomal recessive hereditary disease caused by defects in nucleoside metabolism. The project is the result of a collaboration between the Neuromuscular ...
The SEIP awards a Dr. Pere Soler-Palacín's project on pediatric osteomyelitis
Dr. Pere Soler-Palacín, researcher from Infection in Immunocompromised Pediatric Patients group at Vall d’Hebron Institute of Research (VHIR) and doctor from the Infectious Pathology and Pediatrics Immunodeficiencies Unit at Vall d’Hebron University Hospital, has been awarded with 6,000 euros by the Spanish Society ...
[1 - 2]
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron 2014
I want to receive information from VHIR
Help us to improve our service